Callan Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Callan Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,431	Closed	-$378K	–	304
2023 Q4	$378K	Buy	6,431 +1,000	+18%	+$56.2K	0.04%	149
2023 Q3	$237K	Buy	+5,431	New	+$194K	0.03%	178

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Callan Capital's MRTX Position: Q1 2024 in Review

Callan Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 6,431 shares — an estimated $378K sold.

Callan Capital first reported a position in MRTX in Q3 2023 and held it in 2 quarters. The position peaked at $378K in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Callan Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Callan Capital sold 6,431 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $378K.
Callan Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Callan Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $378K in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Callan Capital's 13F filing for Q1 2024, filed 3 May 2024.